Safety and Tolerability of BAN2401--a Clinical Study in Alzheimer's Disease with a Protofibril Selective Aβ Antibody

Overview

Journal Alzheimers Res Ther

Date 2016 Apr 7

PMID 27048170

Citations 115

Authors

Veronika Logovinsky

Andrew Satlin

Robert Lai

Chad Swanson

June Kaplow

Gunilla Osswald

Hans Basun

Lars Lannfelt

Affiliations

Soon will be listed here.

Abstract

Background: Several monoclonal antibodies for the treatment of Alzheimer's disease (AD) have been in development over the last decade. BAN2401 is a monoclonal antibody that selectively binds soluble amyloid β (Aβ) protofibrils.

Methods: Here we describe the first clinical study with BAN2401. Safety and tolerability were investigated in mild to moderate AD. A study design was used with staggered parallel single and multiple ascending doses, from 0.1 mg/kg as a single dose to 10 mg/kg biweekly for four months. The presence of amyloid related imaging abnormalities (ARIA, E for edema, H for hemorrhage) was assessed with magnetic resonance imaging (MRI). Cerebrospinal fluid (CSF) and plasma samples were analyzed to investigate pharmacokinetics (PK) and effects on biomarkers.

Results: The incidence of ARIA-E/H on MRI was comparable to that of placebo. BAN2401 exposure was approximately dose proportional, with a serum terminal elimination half-life of ~7 days. Only a slight increase of plasma Aβ(1-40) was observed but there were no measurable effects of BAN2401 on CSF biomarkers. On the basis of these findings Phase 2b efficacy study has been initiated in early AD.

Conclusions: BAN2401 was well-tolerated across all doses. The PK profile has guided us for selecting dose and dose regimens in the ongoing phase 2b study. There was no clear guidance for an effective dose based on biomarkers.

Trial Registration Number: NCT01230853 ClinicalTrials.gov Registered October 27, 2010.

Citing Articles

Prasinezumab slows motor progression in Parkinsons disease: beyond the clinical data.

Xiao B, Tan E NPJ Parkinsons Dis. 2025; 11(1):31.

PMID: 39971932 PMC: 11839931. DOI: 10.1038/s41531-025-00886-4.

[Diagnosis and Treatment of Alzheimer's Disease: Current Update].

Yim Y, Moon W J Korean Soc Radiol. 2025; 86(1):6-16.

PMID: 39958494 PMC: 11822271. DOI: 10.3348/jksr.2024.0146.

Drug delivery strategies with lipid-based nanoparticles for Alzheimer's disease treatment.

Jang Y, Kang S, Park H, Lee D, Kim J, Kim J J Nanobiotechnology. 2025; 23(1):99.

PMID: 39930497 PMC: 11809104. DOI: 10.1186/s12951-025-03109-3.

Second-generation anti-amyloid monoclonal antibodies for Alzheimer's disease: current landscape and future perspectives.

Kim B, Kim S, Nam Y, Park Y, Shin S, Moon M Transl Neurodegener. 2025; 14(1):6.

PMID: 39865265 PMC: 11771116. DOI: 10.1186/s40035-025-00465-w.

Targeting Beta-Amyloid Protein with Monoclonal Antibodies: A New Hope for Alzheimer's Treatment.

Ashraf F, Rasool F, Uddin M, Siddiq M, Mustafa M Ann Neurosci. 2025; 31(4):243-245.

PMID: 39840140 PMC: 11744621. DOI: 10.1177/09727531231190989.

References

Walsh D, Lomakin A, Benedek G, Condron M, Teplow D . Amyloid beta-protein fibrillogenesis. Detection of a protofibrillar intermediate. J Biol Chem. 1997; 272(35):22364-72. DOI: 10.1074/jbc.272.35.22364. View

Walsh D, Hartley D, Kusumoto Y, Fezoui Y, Condron M, Lomakin A . Amyloid beta-protein fibrillogenesis. Structure and biological activity of protofibrillar intermediates. J Biol Chem. 1999; 274(36):25945-52. DOI: 10.1074/jbc.274.36.25945. View

Lacor P, Buniel M, Chang L, Fernandez S, Gong Y, Viola K . Synaptic targeting by Alzheimer's-related amyloid beta oligomers. J Neurosci. 2004; 24(45):10191-200. PMC: 6730194. DOI: 10.1523/JNEUROSCI.3432-04.2004. View

Viswanathan A, Chabriat H . Cerebral microhemorrhage. Stroke. 2006; 37(2):550-5. DOI: 10.1161/01.STR.0000199847.96188.12. View

Mastrangelo I, Ahmed M, Sato T, Liu W, Wang C, Hough P . High-resolution atomic force microscopy of soluble Abeta42 oligomers. J Mol Biol. 2006; 358(1):106-19. DOI: 10.1016/j.jmb.2006.01.042. View

Englund H, Sehlin D, Johansson A, Nilsson L, Gellerfors P, Paulie S . Sensitive ELISA detection of amyloid-beta protofibrils in biological samples. J Neurochem. 2007; 103(1):334-45. DOI: 10.1111/j.1471-4159.2007.04759.x. View

Paravastu A, Leapman R, Yau W, Tycko R . Molecular structural basis for polymorphism in Alzheimer's beta-amyloid fibrils. Proc Natl Acad Sci U S A. 2008; 105(47):18349-54. PMC: 2587602. DOI: 10.1073/pnas.0806270105. View

Jicha G . Is passive immunization for Alzheimer's disease 'alive and well' or 'dead and buried'?. Expert Opin Biol Ther. 2009; 9(4):481-91. PMC: 2704502. DOI: 10.1517/14712590902828285. View

Lord A, Gumucio A, Englund H, Sehlin D, Sundquist V, Soderberg L . An amyloid-beta protofibril-selective antibody prevents amyloid formation in a mouse model of Alzheimer's disease. Neurobiol Dis. 2009; 36(3):425-34. DOI: 10.1016/j.nbd.2009.08.007. View

10.

Lublin A, Gandy S . Amyloid-beta oligomers: possible roles as key neurotoxins in Alzheimer's Disease. Mt Sinai J Med. 2010; 77(1):43-9. PMC: 3306842. DOI: 10.1002/msj.20160. View

11.

Ahmed M, Davis J, Aucoin D, Sato T, Ahuja S, Aimoto S . Structural conversion of neurotoxic amyloid-beta(1-42) oligomers to fibrils. Nat Struct Mol Biol. 2010; 17(5):561-7. PMC: 2922021. DOI: 10.1038/nsmb.1799. View

12.

ONuallain B, Freir D, Nicoll A, Risse E, Ferguson N, Herron C . Amyloid beta-protein dimers rapidly form stable synaptotoxic protofibrils. J Neurosci. 2010; 30(43):14411-9. PMC: 2987723. DOI: 10.1523/JNEUROSCI.3537-10.2010. View

13.

Sehlin D, Hedlund M, Lord A, Englund H, Gellerfors P, Paulie S . Heavy-chain complementarity-determining regions determine conformation selectivity of anti-aβ antibodies. Neurodegener Dis. 2010; 8(3):117-23. DOI: 10.1159/000316530. View

14.

Yu X, Zheng J . Polymorphic structures of Alzheimer's β-amyloid globulomers. PLoS One. 2011; 6(6):e20575. PMC: 3110195. DOI: 10.1371/journal.pone.0020575. View

15.

Sperling R, Jack Jr C, Black S, Frosch M, Greenberg S, Hyman B . Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup. Alzheimers Dement. 2011; 7(4):367-85. PMC: 3693547. DOI: 10.1016/j.jalz.2011.05.2351. View

16.

Sehlin D, Englund H, Simu B, Karlsson M, Ingelsson M, Nikolajeff F . Large aggregates are the major soluble Aβ species in AD brain fractionated with density gradient ultracentrifugation. PLoS One. 2012; 7(2):e32014. PMC: 3280222. DOI: 10.1371/journal.pone.0032014. View

17.

Scholl M, Wall A, Thordardottir S, Ferreira D, Bogdanovic N, Langstrom B . Low PiB PET retention in presence of pathologic CSF biomarkers in Arctic APP mutation carriers. Neurology. 2012; 79(3):229-36. DOI: 10.1212/WNL.0b013e31825fdf18. View

18.

Doody R, Thomas R, Farlow M, Iwatsubo T, Vellas B, Joffe S . Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med. 2014; 370(4):311-21. DOI: 10.1056/NEJMoa1312889. View

19.

Salloway S, Sperling R, Fox N, Blennow K, Klunk W, Raskind M . Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med. 2014; 370(4):322-33. PMC: 4159618. DOI: 10.1056/NEJMoa1304839. View

20.

Tucker S, Moller C, Tegerstedt K, Lord A, Laudon H, Sjodahl J . The murine version of BAN2401 (mAb158) selectively reduces amyloid-β protofibrils in brain and cerebrospinal fluid of tg-ArcSwe mice. J Alzheimers Dis. 2014; 43(2):575-88. DOI: 10.3233/JAD-140741. View